

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,844,192 B2  
DATED : January 18, 2005  
INVENTOR(S) : Orlando et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 4,

Line 33, should read -- arginine to lysine substitutions within the amphipathic  $\alpha$  --  
Line 36, should read -- athic  $\alpha$  helix (E4orf6 residues 239-255, SEQ ID NO:26) and --  
Line 39, should read -- ID NO:27). (B) HeLa cells were infected with a recombinant --  
Line 41, should read -- polymerase and then transfected with cDNA under control --  
Line 59, should read -- immunoblotting with MAb 3 (Marton et al. (1990) *J. Virol.* --

Column 5,

Line 63, should read -- tation of the  $\alpha$  helical peptides is the same as seen in FIG. 1B --

Column 6,

Line 2, should read -- R<sub>240.244.251</sub>A, 62%; (G) R<sub>241</sub>E, 0.8%. --  
Line 22, should read -- FIG. 8 shows the key features of the amphipathic  $\alpha$  helix --  
Line 31, should read -- region corresponding to amphipathic  $\alpha$  helix. The arginine --

Column 7,

Line 1, should read -- cytotoxicity is cell type-specific. The cells indi- --  
Line 8, should read -- presence of 600  $\mu$ g/ml G418. After 21 days, the number of --

Column 38,


Line 52, should read -- substitution mutation and an arginine 251 to glutamic acid --

Column 40,

Line 15, should read -- ing of glutamic acid, aspartic acid, serine, threonine, alanine --

Signed and Sealed this

Twelfth Day of July, 2005



JON W. DUDAS  
Director of the United States Patent and Trademark Office